ANL 10.41 Decreased By ▼ -0.09 (-0.86%)
ASC 9.01 Decreased By ▼ -0.18 (-1.96%)
ASL 11.07 Decreased By ▼ -0.06 (-0.54%)
AVN 76.90 Increased By ▲ 0.55 (0.72%)
BOP 5.44 No Change ▼ 0.00 (0%)
CNERGY 5.25 Decreased By ▼ -0.02 (-0.38%)
FFL 6.60 Increased By ▲ 0.03 (0.46%)
FNEL 5.85 Decreased By ▼ -0.05 (-0.85%)
GGGL 10.96 Decreased By ▼ -0.12 (-1.08%)
GGL 16.48 Increased By ▲ 0.04 (0.24%)
GTECH 8.63 Increased By ▲ 0.11 (1.29%)
HUMNL 6.82 Decreased By ▼ -0.07 (-1.02%)
KEL 2.86 Decreased By ▼ -0.04 (-1.38%)
KOSM 3.19 Decreased By ▼ -0.01 (-0.31%)
MLCF 25.69 Decreased By ▼ -1.22 (-4.53%)
PACE 2.95 Decreased By ▼ -0.05 (-1.67%)
PIBTL 5.95 Increased By ▲ 0.04 (0.68%)
PRL 17.21 Increased By ▲ 0.32 (1.89%)
PTC 6.97 No Change ▼ 0.00 (0%)
SILK 1.23 Increased By ▲ 0.06 (5.13%)
SNGP 36.41 Increased By ▲ 0.11 (0.3%)
TELE 10.73 Increased By ▲ 0.14 (1.32%)
TPL 9.03 Decreased By ▼ -0.10 (-1.1%)
TPLP 19.70 Decreased By ▼ -0.21 (-1.05%)
TREET 28.60 No Change ▼ 0.00 (0%)
TRG 76.25 Decreased By ▼ -0.05 (-0.07%)
UNITY 19.88 Increased By ▲ 0.03 (0.15%)
WAVES 12.80 Increased By ▲ 0.14 (1.11%)
WTL 1.37 Increased By ▲ 0.01 (0.74%)
YOUW 5.00 Decreased By ▼ -0.07 (-1.38%)
BR100 4,057 Decreased By -34.6 (-0.85%)
BR30 14,907 Decreased By -45.7 (-0.31%)
KSE100 41,103 Decreased By -245.6 (-0.59%)
KSE30 15,635 Decreased By -101.8 (-0.65%)

FRANKFURT: BioNTech said on Wednesday it would expand an ongoing clinical trial programme to develop new vaccines and patterns of administration for better protection against the dominant Omicron coronavirus variant.

The addition of cohorts to a trial programme initially unveiled in January comes as global infection numbers are on the rise and protection against infection from its established Comirnaty vaccine, co-developed with Pfizer, has waned.

Thanks to 10.3 billion euros ($11.48 billion) in net income in 2021, the German biotech firm plans to spend between 1.4 billion and 1.5 billion euros on research and development this year.

Pfizer-BioNTech seek US approval of second Covid booster for 65+

It also plans to buy back up to $1.5 billion worth of shares over two years and pay a special dividend of 486 million euro in total, or 2 euros per share.

It reiterated its 2022 vaccine revenue guidance of between 13 billion and 17 billion euros.

Comments

Comments are closed.